MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Erasca Inc

Cerrado

2.4 -5.14

Resumen

Variación precio

24h

Actual

Mínimo

2.4

Máximo

2.42

Métricas clave

By Trading Economics

Ingresos

-2.9M

-34M

Margen de beneficio

-768.16

Empleados

103

EBITDA

-2.5M

-38M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+40.5% upside

Dividendos

By Dow Jones

Próximas Ganancias

10 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

264M

684M

Apertura anterior

7.54

Cierre anterior

2.4

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Erasca Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

17 oct 2025, 18:13 UTC

Principales Movimientos del Mercado

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

17 oct 2025, 17:05 UTC

Principales Movimientos del Mercado

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

18 oct 2025, 13:30 UTC

Adquisiciones, fusiones, absorciones

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18 oct 2025, 13:30 UTC

Adquisiciones, fusiones, absorciones

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18 oct 2025, 13:30 UTC

Adquisiciones, fusiones, absorciones

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18 oct 2025, 13:30 UTC

Adquisiciones, fusiones, absorciones

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18 oct 2025, 08:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

17 oct 2025, 23:25 UTC

Adquisiciones, fusiones, absorciones

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 oct 2025, 22:15 UTC

Charlas de Mercado

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 oct 2025, 21:15 UTC

Charlas de Mercado

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

17 oct 2025, 21:07 UTC

Charlas de Mercado

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

17 oct 2025, 21:07 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

17 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 oct 2025, 20:34 UTC

Charlas de Mercado

Deere Is Reaching the End of Its Downcycle -- Market Talk

17 oct 2025, 20:27 UTC

Charlas de Mercado

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

17 oct 2025, 19:46 UTC

Charlas de Mercado

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

17 oct 2025, 19:45 UTC

Charlas de Mercado

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

17 oct 2025, 18:45 UTC

Charlas de Mercado

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

17 oct 2025, 17:51 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 oct 2025, 17:51 UTC

Charlas de Mercado

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

17 oct 2025, 17:44 UTC

Charlas de Mercado

EQT Seen With Long-Term Growth Opportunities -- Market Talk

17 oct 2025, 17:35 UTC

Charlas de Mercado

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

17 oct 2025, 16:20 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

17 oct 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 oct 2025, 16:14 UTC

Charlas de Mercado

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

17 oct 2025, 16:04 UTC

Charlas de Mercado

Home Improvement Demand Is Starting to Pick Up -- Market Talk

17 oct 2025, 15:58 UTC

Charlas de Mercado

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

17 oct 2025, 15:56 UTC

Ganancias

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17 oct 2025, 15:43 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

17 oct 2025, 15:43 UTC

Charlas de Mercado

Amazon's Earnings Are About Sentiment of Consumers, Not Investors -- Market Talk

Comparación entre iguales

Cambio de precio

Erasca Inc Esperado

Precio Objetivo

By TipRanks

40.5% repunte

Estimación a 12 meses

Media 3.4 USD  40.5%

Máximo 6 USD

Mínimo 1 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Erasca Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

3

Comprar

1

Mantener

1

Vender

Puntuación técnica

By Trading Central

1.39 / 1.44Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Very Strong Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
help-icon Live chat